Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1^st February 2022.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through Services Australia website. 

Severe atopic dermatitis

Upadacitinib (Rinvoq®) 15mg and 30 mg tablets are now PBS listed for chronic severe atopic dermatitis. Authority applications for initial and continuing treatment can be made either in real time using HPOS or by telephone.

Mantle cell lymphoma

Acalabrutinib (Calquence®) is now PBS listed for relapsed and/or refractory mantle cell lymphoma. Authority applications for initial and continuing treatment can be made either in real time using HPOS or by telephone.

Multiple sclerosis

Glatiramer acetate (Glatira®) is now PBS listed for multiple sclerosis. Initial and continuing treatment are Authority Required (STREAMLINED).

Severe dry eye syndrome

Hypromellose (Revive Tears®) is now PBS listed under restricted benefit for severe dry eye syndrome including Sjogren’s syndrome.

To learn more about these updates, please contact Services Australia directly.

At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.

Follow our LinkedIn and Facebook pages for more information.